The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study
In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAABRON PRESS
2019-08-01
|
| Series: | Clinical Hematology International |
| Subjects: | |
| Online Access: | https://www.atlantis-press.com/article/125914915/view |
| _version_ | 1797229204298792960 |
|---|---|
| author | Agoston Gyula Szabo Katrine Fladeland Iversen Sören Möller Torben Plesner |
| author_facet | Agoston Gyula Szabo Katrine Fladeland Iversen Sören Möller Torben Plesner |
| author_sort | Agoston Gyula Szabo |
| collection | DOAJ |
| description | In this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011–2016 cohort. After initiation of treatment, the median decrease in the number of patients per each subsequent line of therapy was 22%. Lenalidomide-dexamethasone (n = 156), bortezomib-dexamethasone (n = 107), and bortezomib-lenalidomide-dexamethasone (n = 84) were the most commonly used regimens. The partial response or better rate was 78%, 58%, 55%, and 44% in lines of therapy one to four, respectively. The median (95% confidence interval [CI]) progression-free survival was 18 (15–22), 10 (8–13), 8 (7–10), and 6 (4–8) months in lines of therapy one to four, respectively. The median (95% CI) overall survival (OS) was 4.1 (3.7–4.8) years. Compared with the 2006–2010 cohort, patients in the 2011–2016 cohort had longer OS; 5.3 (4.7 to not reached) versus 3.4 (2.7–4.0) years, p < 0.0001. This was especially true in patients not treated with high-dose therapy and autologous stem cell transplantation; 4.7 (3.2–5.9) versus 2.6 (2.0–3.3) years, p = 0.0052. Patients in the 2011–2016 cohort were on treatment during a greater part of their life and had higher exposure to high-dose melphalan with autologous stem cell transplantation, lenalidomide, pomalidomide, daratumumab, and carfilzomib. |
| first_indexed | 2024-04-24T15:08:52Z |
| format | Article |
| id | doaj.art-c4aa896a1a33474a979c38351aab9f2b |
| institution | Directory Open Access Journal |
| issn | 2590-0048 |
| language | English |
| last_indexed | 2024-04-24T15:08:52Z |
| publishDate | 2019-08-01 |
| publisher | SAABRON PRESS |
| record_format | Article |
| series | Clinical Hematology International |
| spelling | doaj.art-c4aa896a1a33474a979c38351aab9f2b2024-04-02T12:10:39ZengSAABRON PRESSClinical Hematology International2590-00482019-08-011410.2991/chi.d.190805.002The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World StudyAgoston Gyula SzaboKatrine Fladeland IversenSören MöllerTorben PlesnerIn this retrospective study we reviewed the clinical course of every patient with multiple myeloma treated from 2006 to 2016 at Vejle Hospital: 303 patients with a median age of 69 years at diagnosis received a median of four (range 1–18) lines of therapy; 149 in a 2006–2010 cohort and 154 in a 2011–2016 cohort. After initiation of treatment, the median decrease in the number of patients per each subsequent line of therapy was 22%. Lenalidomide-dexamethasone (n = 156), bortezomib-dexamethasone (n = 107), and bortezomib-lenalidomide-dexamethasone (n = 84) were the most commonly used regimens. The partial response or better rate was 78%, 58%, 55%, and 44% in lines of therapy one to four, respectively. The median (95% confidence interval [CI]) progression-free survival was 18 (15–22), 10 (8–13), 8 (7–10), and 6 (4–8) months in lines of therapy one to four, respectively. The median (95% CI) overall survival (OS) was 4.1 (3.7–4.8) years. Compared with the 2006–2010 cohort, patients in the 2011–2016 cohort had longer OS; 5.3 (4.7 to not reached) versus 3.4 (2.7–4.0) years, p < 0.0001. This was especially true in patients not treated with high-dose therapy and autologous stem cell transplantation; 4.7 (3.2–5.9) versus 2.6 (2.0–3.3) years, p = 0.0052. Patients in the 2011–2016 cohort were on treatment during a greater part of their life and had higher exposure to high-dose melphalan with autologous stem cell transplantation, lenalidomide, pomalidomide, daratumumab, and carfilzomib.https://www.atlantis-press.com/article/125914915/viewMultiple myelomaTreatmentReal-world dataLine of therapy |
| spellingShingle | Agoston Gyula Szabo Katrine Fladeland Iversen Sören Möller Torben Plesner The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study Clinical Hematology International Multiple myeloma Treatment Real-world data Line of therapy |
| title | The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study |
| title_full | The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study |
| title_fullStr | The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study |
| title_full_unstemmed | The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study |
| title_short | The Clinical Course of Multiple Myeloma in the Era of Novel Agents: A Retrospective, Single-Center, Real-World Study |
| title_sort | clinical course of multiple myeloma in the era of novel agents a retrospective single center real world study |
| topic | Multiple myeloma Treatment Real-world data Line of therapy |
| url | https://www.atlantis-press.com/article/125914915/view |
| work_keys_str_mv | AT agostongyulaszabo theclinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT katrinefladelandiversen theclinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT sorenmoller theclinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT torbenplesner theclinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT agostongyulaszabo clinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT katrinefladelandiversen clinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT sorenmoller clinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy AT torbenplesner clinicalcourseofmultiplemyelomaintheeraofnovelagentsaretrospectivesinglecenterrealworldstudy |